Storing Thymosin Alpha 1: Best Practices
❄️ Lyophilized Powder Storage
Store vials refrigerated between 2°C and 8°C (36–46°F). For long-term research storage, keep at -20°C or below, desiccated. Stability at room temperature for up to 3 weeks has been reported, but refrigeration is strongly recommended.
💧 Reconstitution
Reconstitute with 1.0 mL Sterile Water for Injection. Use immediately after reconstitution. If storage is required, reconstituted solution may be kept at 4°C for 2–7 days. For long-term storage, consider adding a carrier protein (0.1% HSA or BSA) to prevent degradation.
⚠️ Handling
Avoid repeated freeze-thaw cycles. The standard clinical formulation (Zadaxin) contains 1.6 mg thymosin alpha 1 per vial, formulated with mannitol and sodium phosphate buffer.
📊 Quality Verification
Each batch is verified via RP-HPLC (purity >99.0%), LC-MS/MS (mass confirmation at 3108.3 Da), amino acid analysis, and isoelectric focusing (pI 4.2). Synthesized via solid-phase peptide synthesis (SPPS) to ensure purity and avoid biological contaminants. This product is for research use only (RUO).
References
- Dominari A, Hathaway III D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol, 9(5), 67-78, 2020.
- Goldstein AL, Low TL, McAdoo M, et al. Thymosin alpha1: Isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA, 74(2), 725-729, 1977.
- Li J, Liu CH, Wang FS. Thymosin alpha 1: biological activities, applications and genetic engineering production. Peptides, 31(11), 2151-2158, 2010.
- Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood, 103(11), 4232-4239, 2004.
- King R, Tuthill C. Immune Modulation with Thymosin Alpha 1 research application. Vitamins and Hormones, 102, 151-178, 2016.
- Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin alpha 1 levels in study subjects with chronic inflammatory autoimmune diseases. Clin Exp Immunol, 186(1), 39-45, 2016.
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Tolerability Concerns. U.S. Food and Drug Administration, 2025.
- Elizondo-Riojas MA, Chamow SM, Tuthill CW, et al. NMR structure of human thymosin alpha-1. Biochem Biophys Res Commun, 416(3-4), 356-61, 2011.
- Billich A. Thymosin alpha1. SciClone Pharmaceuticals. Curr Opin Investig Drugs, 3(5), 698-707, 2002.
- Garaci E. Thymosin alpha1: a historical overview. Ann N Y Acad Sci, 1112, 14-20, 2007.
- Tao N, Xu X, Ying Y, et al. Thymosin alpha1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application. Molecules, 28(8), 3539, 2023.
- Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood, 108(7), 2265-74, 2006.
- Serafino A, Pica F, Andreola F, et al. Thymosin alpha1 Activates Complement Receptor-Mediated Phagocytosis in Human Monocyte-Derived Macrophages. J Innate Immun, 6(1), 72-88, 2014.
- Maio M, Mackiewicz A, Testori A, et al. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in study subjects with metastatic melanoma. J Clin Oncol, 28(10), 1780-1787, 2010.
- Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol, 9, 873, 2019.
- Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care, 17(1), R8, 2013.
- Liu Y, Pan Y, Hu Z, et al. Thymosin alpha-1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis, 71(16), 2150-2157, 2020.
- Matteucci C, Grelli S, Balestrieri E, et al. Thymosin alpha 1 and HIV-1: recent advances and future perspectives. Future Microbiol, 12, 141-155, 2017.
- Carraro G, Naso A, Montomoli E, et al. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvanted pandemic H1N1v influenza vaccine. Vaccine, 30(11), 2001-2004, 2012.
- Romani L, Oikonomou V, Moretti S, et al. Thymosin alpha1 represents a potential potent single-molecule-based experimental protocol for cystic fibrosis. Nat Med, 23(5), 590-600, 2017.
- Pica F, Chimenti MS, Gaziano R, et al. Serum thymosin alpha 1 levels in chronic inflammatory autoimmune diseases. Clin Exp Immunol, 186(1), 39-45, 2016.
- Peng R, Xu C, Zheng H, et al. Modified Thymosin Alpha 1 Distributes and Inhibits the Growth of Lung Cancer in Vivo. ACS Omega, 5(18), 10374-10381, 2020.
- Garaci E, Mastino A, Pica F, Favalli C. Combination research application using thymosin alpha 1 and interferon after cyclophosphamide is able to experimental endpoint Lewis lung carcinoma in mice. Cancer Immunol Immunother, 36(5), 355-359, 1993.
- Simonova MA, Ivanov I, Shoshina NS, et al. Aging and Thymosin Alpha-1. Int J Mol Sci, 26(23), 11470, 2025.
Related Research Questions
Want the complete research review?
View Full Thymosin Alpha 1 Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.